Skip to content
Study details
Enrolling now

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib Trial

M.D. Anderson Cancer Center
NCT IDNCT03263572ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

90

Study length

about 10 years

Ages

18+

Locations

1 site in TX

What this study is about

This trial is testing how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome-positive or BCR-ABL positive acute lymphoblastic leukemia that has returned or not responded to treatment. This treatment involves a combination of immunotherapy and chemotherapy drugs.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Blinatumomab
  • 2.Take Cytarabine
  • 3.Take Methotrexate
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

blinatumomab, cytarabine, methotrexate, ponatinib

Drug routes

injection, intravenous, injection (Injection), oral (Oral Tablet)

Endpoints

Primary: Event-free survival, Overall response rate (ORR) in relapsed/refractory ALL, Overall survival, Relapse-free survival

Body systems

Oncology